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olites of the mevalonate pathway which trigger proliferation of a
subset of cytotoxic gamma, delta T cells and cytokine release.
Several studies are now in progress investigating whether this
immunomodulatory effect of zoledronic acid can be utilized in
oncology to enhance its therapeutic potential beyond the well
established inhibition of tumour-induced osteolysis.
doi:10.1016/j.ejcsup.2006.04.047
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METASTASES IN RESECTABLE NON SMALL CELL LUNG
CARCINOMA: A CASE–CONTROL STUDY AND
PREVALENCE DATA
M. Papottia, T. Kalebicb, M. Volantea, E. Bacilloa, S. Cappiaa, G.V.
Scagliottia. aUniversity of Turin at San Luigi Hospital, Turin,
Italy; bNovartis Pharma, East Hanover, USA.
Background: Non small cell lung cancer (NSCLC) is the leading
cause of cancer related deaths, mostly secondary to diffuse extra-
thoracic spread of the disease in several organs and systems. Bone
metastases (BM) may be present at diagnosis or develop in the fol-
low up, are associated with a worse prognosis, and currently there
are no chemical or biological markers predicting their clinical
onset. Several molecules are potential factors favouring bone dis-
semination by cancer cells, including cell cycle proteins, angioge-
netic factors, extra-cellular matrix proteins and their inhibitors,
serum and plasma proteins implicated in bone resorption mecha-
nisms. Increased levels of some of these molecules (periostin, BSP
and osteopontin) were found in colon, breast and prostate can-
cers. Their role in lung cancer is controversial. Aim of this study
was to investigate the predictive and prognostic value of bone
resorption-related molecules in favouring or modulating the colo-
nisation of bone tissue during haematogenous spread of NSCLC.
Methods: Thirty cases of resected NSCLC which developed BM
(group A – mean follow up time 27.2 months) were matched for
several clinico-pathological parameters (including age, sex, stage
of the disease, histology, differentiation grade, adjuvant therapy)
to 30 cases of resected NSCLC without any metastases (group B –
mean follow up time 75.1 months) and 26 resected NSCLC with
non-bone metastases (group C – mean follow up 21.1 months).
Primary tumor samples were investigated by a standard auto-
mated immunoperoxidase procedure for 10 markers previously
recognized to be involved in bone resorption or metastatization
process (cathepsin K, bone sialoprotein [BSP],VEGF, MMP-2, p53,
RECK, TIMP-1, CD-117, Ki-67 and TRAcP). For statistical analysis,
the staining distribution in tumor cells was assessed by a semi-
quantitative score (0, <10%, 10–50%, >50% positive tumor cells).
Differences among groups were estimated by v2 test, whereas
the prognostic impact of clinico-pathological parameters and
marker expression was evaluated by univariate and multivariate
analyses. An additional series of 120 resected consecutive NSCLC
was also tested for BSP expression prevalence (group D).
Results: Among the different markers investigated, BSP expres-
sion was significantly higher in bone metastatic cases (80%)
compared to 20% and 31% of groups B (non metastatic) and C
(non-bone metastases), respectively (p < 0.001). BSP expression
did not show any difference according to tumor histotype or
any other characteristics. In addition, taking all the three groups
together, or the metastatic groups (groups A and C) alone, BSP
expression was also shown to be related to poor outcome
(p = 0.02 by Mantel–Cox test). None of the other markers was dif-
ferentially expressed within the groups or demonstrated a prog-
nostic impact, both in terms of overall survival and of time
interval to metastases. BSP was further estimated in 120 resected
NSCLCs (M:F ratio 3:1; mean age 67 years; histotype: adenocarci-
nomas 55%, squamous cell carcinoma 39%, others 6%; stages: I
54%, II 17%, III 29%) and a prevalence of 40% observed, without
any statistically significant difference according to histotype or
other clinico-pathological parameters.
Discussion: In this study, we have shown that BSP is signifi-
cantly more expressed in a series of NSCLC metastatic to bone
as compared with matched control groups of NSCLC (metastatic
or non metastatic) which did not progress to bone in the same
period of time. BSP expression was also found to be predictive
of poor prognosis, but not related to the time interval to distant
spread. Moreover, in a large consecutive series of resected NSCLC
we observed a prevalence of BSP protein expression of 40%. Inter-
estingly, this percentage of positivity is intermediate between
that in group A on the one side, and groups B and C on the other.
The biological significance of BSP expression in tumors progress-
ing to bone metastases is not fully understood. The balance of
bone apposition and resorption involves several molecules,
locally produced or possibly blood-born, which act through differ-
ent specific circuits. BSP itself may be powering the effect of bone
resorption and facilitate bone colonisation by tumor cells. In
in vitro models, BSP favoured cancer cell invasiveness through a
linkage with integrins and MMP2. Inhibition of BSP-MMP2 com-
plex was able to block BSP-enhanced invasiveness. Our findings
suggest that in the future NSCLC patients with BSP expression,
may benefit of BSP inhibitors and may also be reasonably good
candidates for preventive treatments (i.e., bone metabolic agents)
in order to block, reduce or delay the osteotropism of cancer cells.
In conclusion, immunohistochemical expression of BSP in resected
NSCLC strongly predicts bone dissemination, and may therefore
be useful in selecting patients for treatments targeted to contrast
bone metastatic spread.
doi:10.1016/j.ejcsup.2006.04.048
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CD133 positive ‘‘Cancer Stem Cells’’ (CSC) have been shown to ini-
tiate and maintain glioblastoma growth. The first aim of our stud-
ies was to further characterize CD133+ cells in gliomas of different
grades with respect to their prospective origin and differentiation
potential. CD133+ cells could be identified in gliomas grade II–IV.
Co-expression of CD133 and Musashi-1 indicated a neural stem
cell character of CD133+ cells. Expression of both markers was
clearly grade dependent with up to 20% of cells being CD133+ in
GBM. Under different culture conditions, CD133+ cells isolated
from gliomas lost CD133 expression and started expression of
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glial, neuronal and endothelial markers demonstrating pluripo-
tency of differentiation potential. These findings point towards
an essential role of CD133/Musashi-1+ cells in glioma biology
making these cells a potential target for future therapies. On the
other hand, stem cells are currently evaluated as potential carriers
of anti-glioma therapies. Therefore, the second aim of our studies
was to assess intracerebral distribution patterns of mesenchymal
stroma cells (MSC) after local versus systemic application. Human
MSC (hMSC) were isolated from bone marrow biopsies carried out
for haematological indications. U373-GFP gliomas were generated
by orthotopic implantation. After local application of hMSC,
migration of hMSC towards the tumor was observed. In a second
setting, intravenously administered MSC transfected with a RFP/
Tie-2 promotor gene showed extensive tropism to the glioma.
RFP expression indicated integration of MSC into the intratumoral
vasculature. Therefore, MSC might be valuable candidates as car-
riers for an anti-tumor, especially an anti-vascular gene therapy.
Altogether, stem cells might play roles in the ‘‘cause’’ as well as
in the ‘‘cure’’ of glioma.
doi:10.1016/j.ejcsup.2006.04.049
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Some of the most potent cytotoxic drugs, e.g. ifosfamide, are
hampered in their effectiveness in certain cancers due to severe
side effects in elder patients. A way to circumvent this problem
is to employ gene directed enzyme prodrug therapy by delivering
a second site of drug activation at the tumor site. This concept
was developed using ifosfamide as the prodrug and the metabol-
ising cytochrome P450 subenzyme CYP2B1 for conversion. The
gene was transfected in 293 cells. To protect the genetically mod-
ified cells from the host immune system and, conversely, to pro-
tect the host from the allogenic cells, those were
microencapsulated in sodium cellulose (diameter  0.8 mm). In
an experimental setting, the microcapsules containing CYP2B1
expressing cells were directly injected in pre-established human
pancreatic adenocarcinomas on nude mice. After treatment with
low-dose ifosfamide, 20% CR was achieved. Identical results were
obtained in a syngenic rat pancreatic carcinoma model. Further,
this experimental approach has very successfully been applied
to experimental peritoneal carcinomatosis as well as naturally
occurring breast carcinomas in dogs. For clinical use, a feasibility
study in pigs demonstrated the safety of agiographic intra-arterial
placement into a pancreatic artery. After completion of IRB and
registration with authorities, a clinical phase I/II study in patients
with inoperable pancreatic adenocarcinoma was performed. The
concept proved to be safe. 2/14 patients demonstrated a partial
remission, the reminder was stable. Mean OS was 44 weeks,
one year survival 32%.
doi:10.1016/j.ejcsup.2006.04.050
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Vaccination against cancer has had a variable history, with
claims of success often fading into disappointment. The reasons
for this include poor vaccine design, inadequate understanding
of the nature of the immune response, and a lack of objective
measures to evaluate performance. The characterization of
tumor-associated antigens (TAAs) recognized by human T lym-
phocytes in a MHC-restricted fashion has opened new possibili-
ties for specific vaccine approaches to the treatment of human
cancers. Recent findings include vaccine formulation, relevant
knowledge concerning mechanisms of induction of effective
immunity from preclinical models, and translation into clinical
trials. We now have novel vaccine strategies to activate specific
attack on tumor cells and we understand more about activation
and regulation of immunity against cancer (co-stimulation versus
co-inhibition, regulatory T cells). We also have modern assays
using surrogate markers (MHC multimer analysis, IFN-c Elispot
assay) to correlate with clinical effects. Although early clinical
vaccine trials based on synthetic peptides, proteins, ‘naked’
DNA, tumor-RNA, dendritic cells, and recombinant vaccinia
viruses indicate that vaccines can induce immune responses
and tumor regression in some cancer patients, careful study
design and use of standardized clinical and immunological crite-
ria are needed. Basic principles of tumor vaccination and clinical
trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.051
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Disseminated tumor cells in tissue, blood or bone marrow sam-
ples of patients with thyroid carcinoma are detectable by PCR
assays by using different molecular tumor markers. The aim of
our study was to correlate the results of molecular staging with
the patients’ follow-up.
Patients and Methods: Eighty-seven tumor, 43 blood and 14 bone
marrow samples of patients with thyroid carcinomas were
obtained during surgery and subjected to Cytokeratin 20 (CK20)
and PreproGastrin-releasing peptide (PreproGRP) PCR systems.
Results: An expression of CK20 transcripts was detected in all of
the medullary thyroid carcinomas (MTC), 63% of follicular thyroid
carcinomas (FTC), 43% of papillary (PTC) and 17% of anaplastic
(ATC) carcinomas . In FTC and PTC an expression of CK20 was
seen in 54% in primary tumors and in 42% in soft tissue or lymph
node recurrence. 75% of the patients with CK20-positive FTC were
disease-free at follow-up compared to none of the patients with
CK20-negative FTC. PreproGRP was found in 100% of MTC tissue
samples. Overall, disseminated tumor cells of CK20-positive
carcinomas were detected in 33% of the blood samples. In MTC,
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